Possible “Game-Changer in Treatment of Type 2 Diabetes” Canagliflozin (Invokana) Drug Reduces Risks of Cardiovascular Disease, Heart Failure Hospitalization, and Kidney Disease Progression, According to Study Published in NEJM

A drug that lowers blood sugar levels for people with type 2 diabetes has also been revealed to significantly reduce the risk of both cardiovascular and kidney disease. The study by The George Institute for Global Health has major implications for the treatment of type 2 diabetes, which affects approximately 450 million people worldwide. The findings published online on June 12, 2017 in the New England Journal of Medicine found that the drug canagliflozin (Invokana) reduced the overall risk of cardiovascular disease by 14 per cent and reduced the risk of heart failure hospitalization by 33 per cent. It was also shown to have a significant impact on the progression of renal disease. Professor Bruce Neal, of The George Institute for Global Health, said the findings, which were presented at the American Diabetes Association Conference in San Diego (June 9-13) were exciting and offered real hope to people suffering from type 2 diabetes. "Coronary heart disease is the biggest killer by far for people with type 2 diabetes. Our findings suggest that not only does canagliflozin significantly reduce the risk of heart disease, it also has many other benefits too. We found it also reduced blood pressure and led to weight loss. Type 2 diabetes is growing rapidly all over the world and we need drugs that not only deal with glucose levels, but that also protect the many millions of people from the very real risks of stroke and heart attack." The study is particularly important to Australiaa because approximately 65% of all cardiovascular deaths occur in people with diabetes or pre-diabetes, and diabetes is also the leading cause of end-stage kidney disease. It also reinforces the findings from a previous study which also showed a reduced risk of cardiovascular disease associated with blood-sugar-level-lowering drugs. The NEJM article is titled "Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes."
Login Or Register To Read Full Story